Deregulation of the Interleukin-7 Signaling Pathway in Lymphoid Malignancies

A fully human anti-IL-7Rα antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia

(2019) Padma Akkapeddi et al.   LEUKEMIA

Oncogenic basic amino acid insertions at the extracellular juxtamembrane region of IL7RA cause receptor hypersensitivity

(2019) Livia Weijenborg Campos et al.   BLOOD

Epigenetic silencing of SOCS 5 potentiates JAK ‐ STAT signaling and progression of T‐cell acute lymphoblastic leukemia

(2019) Nitesh D. Sharma et al.   CANCER SCIENCE

IL-7R is essential for leukemia-initiating cell activity and pathogenesis of T-cell acute lymphoblastic leukemia

(2019) Sara González-García et al.   BLOOD

New anti-IL-7Rα monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models

(2019) Julie A. Hixon et al.   LEUKEMIA

Flip the coin: IL-7 and IL-7R in health and disease

(2019) João T. Barata et al.   NATURE IMMUNOLOGY

Deleterious and Oncogenic Mutations in the IL7RA

(2019) Lívia Weijenborg Campos et al.   Cancers

HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development

(2018) Charles E. de Bock et al.   Cancer Discovery

Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations

(2018) Emilee Senkevitch et al.   Oncotarget

IL7R is associated with CNS infiltration and relapse in pediatric B-cell precursor acute lymphoblastic leukemia

(2018) Ameera Alsadeq et al.   BLOOD

“Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway

(2018) Emira Bousoik et al.   Frontiers in Oncology

STAT5BN642H is a driver mutation for T cell neoplasia

(2017) Ha Thi Thanh Pham et al.   JOURNAL OF CLINICAL INVESTIGATION

Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia

(2017) S Degryse et al.   LEUKEMIA

JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias

(2017) C Delgado-Martin et al.   LEUKEMIA

The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling

(2017) T Girardi et al.   LEUKEMIA

The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia

(2017) Yu Liu et al.   NATURE GENETICS

Identification of a novel functional JAK1 S646P mutation in acute lymphoblastic leukemia

(2017) Qian Li et al.   Oncotarget

Immunoregulation by IL-7R-targeting antibody-drug conjugates: overcoming steroid-resistance in cancer and autoimmune disease

(2017) Masahiro Yasunaga et al.   Scientific Reports

Therapeutic targeting of IL-7R  signaling pathways in ALL treatment

(2016) S. D. Cramer et al.   BLOOD

TC-PTP and PTP1B: Regulating JAK–STAT signaling, controlling lymphoid malignancies

(2016) Kelly A. Pike et al.   CYTOKINE

Loss-of-function mutations of Dynamin 2 promote T-ALL by enhancing IL-7 signalling

(2016) C S Tremblay et al.   LEUKEMIA

MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia

(2016) K Canté-Barrett et al.   LEUKEMIA

Novel dynamin 2 mutations in adult T-cell acute lymphoblastic leukemia

(2016) Zheng Ge et al.   Oncology Letters

Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma

(2015) Ramona Crescenzo et al.   CANCER CELL

Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia

(2015) C. Vicente et al.   HAEMATOLOGICA

The origin of relapse in pediatric T-cell acute lymphoblastic leukemia

(2015) C. Vicente et al.   HAEMATOLOGICA

Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities

(2015) Elisabeth Losdyck et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Identification of mutant alleles ofJAK3in pediatric patients with acute lymphoblastic leukemia

(2015) Changhong Yin et al.   LEUKEMIA & LYMPHOMA

ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling

(2015) Steven Goossens et al.   Nature Communications

Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells

(2015) Can Küçük et al.   Nature Communications

Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia

(2015) C. Vicente et al.   HAEMATOLOGICA

The origin of relapse in pediatric T-cell acute lymphoblastic leukemia

(2015) C. Vicente et al.   HAEMATOLOGICA

Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia

(2015) Kathryn G. Roberts et al.   NEW ENGLAND JOURNAL OF MEDICINE

Uncovering the pathogenesis of large granular lymphocytic leukemia—novelSTAT3andSTAT5bmutations

(2014) Hanna L. M. Rajala et al.   ANNALS OF MEDICINE

Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia

(2014) M. J. Kiel et al.   BLOOD

Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia

(2014) C. Shochat et al.   BLOOD

JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model

(2014) S. Degryse et al.   BLOOD

Targeting oncogenic interleukin-7 receptor signalling withN-acetylcysteine in T cell acute lymphoblastic leukaemia

(2014) Marc R. Mansour et al.   BRITISH JOURNAL OF HAEMATOLOGY

The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse

(2014) O. R. Bandapalli et al.   HAEMATOLOGICA

Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential

(2014) Louise M. Treanor et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia

(2014) M Kontro et al.   LEUKEMIA

Interleukin 7 and thymic stromal lymphopoietin: from immunity to leukemia

(2013) Noa Tal et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma

(2013) A Bouchekioua et al.   LEUKEMIA

Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2

(2012) D. van Bodegom et al.   BLOOD

Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia

(2012) M. Porcu et al.   BLOOD

Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia

(2012) S. L. Maude et al.   BLOOD

Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia

(2012) Kathryn G. Roberts et al.   CANCER CELL

Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia

(2012) T Bains et al.   LEUKEMIA

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia

(2012) Jinghui Zhang et al.   NATURE

JAK/STAT signaling in hematological malignancies

(2012) W Vainchenker et al.   ONCOGENE

Janus Kinase 3–Activating Mutations Identified in Natural Killer/T-cell Lymphoma

(2012) Ghee Chong Koo et al.   Cancer Discovery

FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma

(2011) N. E. Elliott et al.   BLOOD

PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia

(2011) M. Kleppe et al.   BLOOD

IL-7 Contributes to the Progression of Human T-cell Acute Lymphoblastic Leukemias

(2011) A. Silva et al.   CANCER RESEARCH

Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin's lymphoma and T-cell non-Hodgkin's lymphoma

(2011) M. Kleppe et al.   HAEMATOLOGICA

Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors

(2011) T. Hornakova et al.   HAEMATOLOGICA

Gain-of-function mutations ininterleukin-7 receptor-α(IL7R) in childhood acute lymphoblastic leukemias

(2011) Chen Shochat et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia

(2011) Priscila P Zenatti et al.   NATURE GENETICS

Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ

(2010) Geoff M. Gordon et al.   BIOCHEMICAL JOURNAL

Reversible phosphorylation in haematological malignancies: Potential role for protein tyrosine phosphatases in treatment?

(2010) Roberta R. Ruela-de-Sousa et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia

(2010) R. C. Harvey et al.   BLOOD

Interleukin-7 Receptor Signaling Network: An Integrated Systems Perspective

(2010) Megan J Palmer et al.   Cellular & Molecular Immunology

Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia

(2010) Maria Kleppe et al.   NATURE GENETICS

Selective ablation of the YxxM motif of IL-7Rα suppresses lymphomagenesis but maintains lymphocyte development

(2010) L C Osborne et al.   ONCOGENE

Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7-induced signaling

(2010) Y. Rochman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group

(2009) L. Hertzberg et al.   BLOOD

Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia

(2009) L. J. Russell et al.   BLOOD

JAK1 mutations are not frequent events in adult T-ALL: a GRAALL study

(2009) Vahid Asnafi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Functional coexpression of Interleukin (IL)-7 and its receptor (IL-7R) on Hodgkin and Reed-Sternberg cells: Involvement of IL-7 in tumor cell growth and microenvironmental interactions of Hodgkin's lymphoma

(2009) Lara Cattaruzza et al.   INTERNATIONAL JOURNAL OF CANCER

Acute Lymphoblastic Leukemia-associated JAK1 Mutants Activate the Janus Kinase/STAT Pathway via Interleukin-9 Receptor α Homodimers

(2009) Tekla Hornakova et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

TSLP and IL-7 use two different mechanisms to regulate human CD4+T cell homeostasis

(2009) Ning Lu et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Activating mutation in the TSLPR gene in B-cell precursor lymphoblastic leukemia

(2009) E Chapiro et al.   LEUKEMIA

CD45 recruits adapter protein DOK-1 and negatively regulates JAK–STAT signaling in hematopoietic cells

(2009) Liangtang Wu et al.   MOLECULAR IMMUNOLOGY

Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemia

(2009) Charles G Mullighan et al.   NATURE GENETICS

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia

(2009) A. Yoda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

JAK mutations in high-risk childhood acute lymphoblastic leukemia

(2009) C. G. Mullighan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural and Biophysical Studies of the Human IL-7/IL-7Rα Complex

(2009) Craig A. McElroy et al.   STRUCTURE

Somatic Mutations of JAK1 and JAK3 in Acute Leukemias and Solid Cancers

(2008) E. G. Jeong et al.   CLINICAL CANCER RESEARCH

Somatically acquiredJAK1mutations in adult acute lymphoblastic leukemia

(2008) Elisabetta Flex et al.   JOURNAL OF EXPERIMENTAL MEDICINE